DOCSLIB.ORG

IMPURITY REFERENCE EP Impurities, USP Impurities, BP Impurities, Labeled Impurities & Pharmaceutical Impurities

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IMPURITY REFERENCE EP Impurities, USP Impurities, BP Impurities, Labeled Impurities & Pharmaceutical Impurities IMPURITY REFERENCE EP Impurities, USP Impurities, BP Impurities, Labeled Impurities & Pharmaceutical Impurities lgcstandards.com [email protected] Chemical Name CAS Number Catalog Number Abacavir 136470-78-5 A104990 Abacavir Sulfate 188062-50-2 A105000 Abacavir Carboxylate 384380-52-3 A105005 ent-Abacavir 136470-79-6 A105015 Abacavir 5’-Phosphate 136470-77-4 A105020 Abacavir 5’-4-Chloro-6-methylpyrimidine-2,5-diamine 1443421-69-9 A105035 Acarbose D-Fructose Impurity 1013621-79-8 A123515 Acebutolol Dimer Impurity 1330165-98-4 A123890 Aceclofenac Benzyl Ester 100499-89-6 A130410 Aceclofenac Ethyl Ester 139272-67-6 A130415 Aceclofenac Methyl Ester 139272-66-5 A130420 bis(2-Acetamido-1,3,4-thiadiazol-5-yl) Disulfide 99055-56-8 A132750 4-Acetamidobenzenesulfonic Acid 121-62-0 A141875 2-Acetamidophenol 614-80-2 A158490 N-(5-Acetamido-1,3,4-thiadiazole-2-yl) Acetazolamide A160000 3-Acetamidophthalic Acid 15371-06-9 A161140 Acetaminophen Acetate (Acetaminophen Impurity) 2623-33-8 A161215 N-[5-(Acetylamino)-2-hydroxyphenyl]-N-(4-hydroxyphenyl)acetamide 98966-17-7 A161245 Acetic Aceclofenac 1215709-75-3 A161550 Acetoacetamide 5977-14-0 A161805 9-[4-Acetoxy-3-(acetoxymethyl)butyl]-2-amino-6-chloropurine 97845-60-8 A164140 1-[(2β,3α,5α,16β,17β)-3-(Acetyloxy)-17-hydroxy-2-(1-piperidinyl)androstan- 50587-95-6 A164495 16-yl]-1-methylpiperidinium Bromide (2β,3α,5α,16β,17β)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1- 119302-24-8 A165650 pyrrolidinyl)androstane 21-Acetoxy-11β-hydroxy-16α,17α-propylmethylenedioxpregna-1,4-diene- 51333-05-2 A165740 3,20-dione 21-Acetoxy-11β-hydroxypregna-1,4,16-triene-3,20-dione 3044-42-6 A165755 N-Acetyl-N-[2-(7-methoxy-1-naphthalenyl)ethyl]acetamide 1379005-34-1 A167620 20α-Acetoxy-4-pregnen-3-one 5035-09-06 A167690 1-Acetyl-2-imidazolidinone 5391-39-9 A167955 Acyclovir N,O-Diacetate 75128-73-3 A167995 N2-Acetyl Acyclovir 110104-37-5 A168015 N-Acetyl Adamantamine 880-52-4 A168050 5-(Acetylamino)-1,3,4-thiadiazole-2-sulfonic Acid Potassium Salt A168090 2-Acetamido-5-mercapto-1,3,4-thiadiazole 32873-56-6 A168105 4-Acetylamino-2-chlorophenol 3964-54-3 A168175 4-Acetylamino-3-hydroxybenzoic Acid Ethyl Ester 1346604-18-9 A168250 3'-N-[[4-(Acetylamino)phenyl]sulfonyl]-3'-N-demethyl Azithromycin 612069-30-4 A168295 20 Martin Ross Avenue North York, ON Canada, M3J 2K8 2 www.trc-canada.com [email protected] +1-416-665-9696 Chemical Name CAS Number Catalog Number N-Acetyl-4-aminosalicylic Acid 50-86-2 A168325 Acetanilide (Acetylaniline) 103-84-4 A168330 21-O-Acetyl Dexamethasone 1177-87-3 A168480 N-Acetyl Cefpodoxime Proxetil 947692-15-1 A168610 3-Acetylbenzophenone 66067-44-5 A170975 3-Acetylaminophthalic Anhydride 6296-53-3 A170980 4-Acetoxy-2',4'-difluorobiphenyl 59089-67-7 A171095 Acetylclonidine 54707-71-0 A172120 3-Acetyl-17-deacetyl Rocuronium Bromide 1190105-63-5 A172180 N-Acetyl-2,6-dichlorodiphenylamine 84803-53-2 A173570 5-Acetyl-10,11-dihydro-5H-dibenzo[b,f]azepine 13080-75-6 A173695 3’-Acetyl-4’-(2,3-epoxypropoxy)butyranilide 28197-66-2 A173780 3-O-Acetyl Ezetimibe 1044664-24-5 A173795 Acetylfentanyl 3258-84-2 A175000 N-(3-Acetyl-4-hydroxyphenyl)butanamide 40188-45-2 A178975 (±)-N-[3-Acetyl-4-[2-hydroxy-3-[(1- 57898-79-0 A178980 methylethyl)amino]propoxy]phenyl]propanamide Monohydrochloride 1-Acetylimidazolidinethione 5391-52-6 A179185 O-Acetyl Losartan 1006062-27-6 A185300 3-(Acetylmethylamino)-1-propanesulfonic Acid Calcium Salt 233591-26-9 A186550 N-Acetyl Metoclopramide 5608-13-9 A186860 N2-Acetyl Neamine A187013 7-Acetyl Paclitaxel 92950-39-5 A187375 N-Acetylpiperazine-N’-(4-phenol) Ketoconazole 1346598-39-7 A187500 3-Acetylpyridine 350-03-8 A187600 17-Acetyloxy-pregna-1,4-diene-3,20-dione (~90%) 2668-74-8 A187710 3-Acetyl Rocuronium Bromide 122483-73-2 A187730 Acetylsalicylic Anhydride 1466-82-6 A187785 Acetylsalicylsalicylic Acid 530-75-6 A187788 4'-Acetyl Simvastatin 145576-25-6 A187795 N-Acetyl Sulfamethoxazole 21312-10-7 A187885 13,14-Anhydro-10-desacetyl Baccatin 1217248-58-2 A187928 (4-Acetyl-L-Serine)Leuprorelin Trifluoroacetic Acid Salt A187985 (3S,4aR,5S,6S,11R,12R,12aR)-5-(Acetyloxy)-1,2,3,4,4a,5,6,7,8,11,12,12a- dodecahydro-6,11,12-trihydroxy-9,12a,13,13-tetramethyl-4-methylene-8-oxo- 959572-72-6 A188100 6,10-methanobenzocyclodecen-3-yl β-(Dimethylamino)-benzenepropanoate Paclitaxel Impurity O 219783-77-4 A188120 (11β,16α)-21-(Acetyloxy)-11,16,17-trihydroxypregna-1,4,14-triene-3,20- 131918-72-4 A188360 dione 20 Martin Ross Avenue North York, ON Canada, M3J 2K8 3 www.trc-canada.com [email protected] +1-416-665-9696 Chemical Name CAS Number Catalog Number 2-Acetylthioethanesulfonic Acid 69536-71-6 A188740 7α-Acetylthio-17α-ethoxymethyl Testosterone A188745 3-Acetylthio-2-methylpropionic Acid 33325-40-5 A188775 N-Acetyl Tizanidine 173532-15-5 A188870 N-Acetyl L-Thyroxine 26041-51-0 A188890 1-O-Acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 6974-32-9 A189330 5-Acetyl-3-chloroiminodibenzyl 25961-11-9 A189530 Acotiamide Methyl Ether 185103-80-4 A190265 Acyclovir 59277-89-3 A192400 Acyclovir Acetate 102728-64-3 A192410 Acyclovir N-Methyl-L-valinate Hydrochloride 1346617-39-7 A192430 Acyclovir Formacetal Dimer A192435 Acyclovir N-Methylene Dimer 1797131-64-6 A192450 o-Adamantylanisole 43109-77-9 A208250 Adapalene Methyl Ester 106685-41-0 A225010 7-ADCA Pivalamide 146794-70-9 A235000 Agomelatine Dimer Acetamide 1385018-58-5 A430020 Agomelatine Dimer Urea 185421-27-6 A430025 Albendazole Sulfone 75184-71-3 A511615 Albendazole Sulfoxide 54029-12-8 A511620 Albuterol Aldehyde Hemisulfate 156339-88-7 A514495 Albuterol Methyl Ether Hydrochloride Salt A514510 Albuterol Dimer Ether, 75% 147663-30-7 A514520 (3R,4R,5S)-4-(Acetylamino)-5-amino-3-(1-methylethoxy)-1-Cyclohexene-1- 1052063-36-1 A549303 carboxylic Acid Ethyl Ester Allylamine 107-11-9 A549550 6-Allyl-8β-carboxyergoline 81409-74-7 A549620 Almotriptan N-Oxide Hydrochloride Salt 1391054-49-1 A575210 Aloe-emodin 481-72-1 A575400 rac-cis-Ambroxol 107814-37-9 A575905 Ambroxol Cyclic Impurity Hydrochloride 15942-08-2 A575910 6-Aminoadamantane-1,3-diol 918830-94-1 A580150 Amino Albendazole 80983-36-4 A580945 Amino Albendazole Sulfone 80983-34-2 A580950 4-Aminoanastrozolium Bromide 906813-01-2 A583720 N-(4-Aminobenzenesulfonyl) Sulfamethoxazole 135529-16-7 A591480 3-Aminobenzoic Acid 1999-05-08 A591490 2-Amino-5(6)-benzoylbenzimidazole 52329-60-9 A593760 20 Martin Ross Avenue North York, ON Canada, M3J 2K8 4 www.trc-canada.com [email protected] +1-416-665-9696 Chemical Name CAS Number Catalog Number N-(4-Aminobenzoyl)-L-glutamic Acid 4271-30-1 A593770 N-(4-Aminobenzoyl)-β-alanine 7377-08-04 A593795 N-[1-(Aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole- 1863065-92-2 A593935 3-carboxamide 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethylester N-Methyl-L- 1346747-65-6 A597115 Valine (S)-4-(4-Aminobenzyl)-2-(1H)-oxazolidinone 152305-23-2 A599500 5-Amino-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-1,3- 60166-98-5 A601550 benzenedicarboxamide 4-Amino-1-[3,5-bis-O-(4-chlorobenzoyl)-2-deoxy-α-D-erythro- 1140891-02-6 A601700 pentofuranosyl]-1,3,5-triazin-2(1H)-one 4-Amino-1-[3,5-bis-O-(4-chlorobenzoyl)-2-deoxy-β-D-erythro-pentofuranosyl]- 1034301-08-0 A601705 1,3,5-triazin-2(1H)-one 2-(2-Amino-5-bromobenzoyl)pyridine 1563-56-0 A601785 6-Amino-5-bromoquinoxaline 50358-63-9 A601885 2-Amino-5-bromo-N-cyclohexyl-N-methylbenzylamine Dihydrochloride 10076-98-9 A601925 (S)-2-Aminobutyramide Hydrochloride 7682-20-4 A602890 α-[(Aminocarbonyl)thio]-4-[2-(5-ethyl-2-pyridinyl)ethoxy]benzenepropanoic Acid Ethyl Ester 868754-41-0 A603065 (Pioglitazone Impurity) 3-Amino-4-carbamoylpyrazole Hemisulfate 27511-79-1 A603076 1-[[(6R,7R)-7-Amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3- 103121-85-3 A603160 yl]methyl]-1-methylpyrrolidinium Chloride 7-Amino-3-chloro-3-cephem-4-carboxylic Acid 53994-69-7 A603305 4-Amino-5-chloro-2-methoxybenzoic Acid 7206-70-4 A603320 (1S,4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-carboxylate 1246819-78-2 A603360 4-Amino-6-chloro-1,3-benzenedisulfonamide 121-30-2 A603375 7-Aminocephalosporanic Acid 957-68-6 A603415 4-Amino-5-chloro-2,1,3-benzothiadiazole 30536-19-7 A603430 4-Amino-2-chloro-6,7-dimethoxyquinazoline 23680-84-4 A603439 2-Amino-6-chloropurine 10310-21-1 A603505 (1S,4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol 172015-79-1 A603506 Hydrochloride 3-Amino-4-(2-chlorophenyl)-6-nitro-2(1H)-quinolinone 55198-89-5 A603590 (Clonazepam Impurity) 1-Aminocyclopropane-1-carboxylic Acid Methyl Ester Hydrochloride 72784-42-0 A603600 5-Amino-2-cyanobenzotrifluoride 654-70-6 A603630 (1S,4R)-cis-4-Amino-2-cyclopentene-1-methanol D-Tartrate 229177-52-0 A603640 2-Amino-N-cyclohexyl-N-methylbenzylamine 57365-08-9 A603680 7-Amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3- 172426-88-9 A603780 quinolinecarboxylic Acid (1R,3S)-3-[2-Amino-6-(cyclopropylamino)-9H-purin-9- 208762-35-0 A603795 yl]cyclopentanemethanol [2-[(2-Amino-4-chlorophenyl)amino]phenyl](4-methyl-1- 65514-71-8 A603880 piperazinyl)methanone 3’-Amino-3’-deoxythymidine 52450-18-7 A604250 20 Martin Ross Avenue North York, ON Canada, M3J 2K8 5 www.trc-canada.com [email protected] +1-416-665-9696 Chemical Name CAS Number Catalog Number 7-Aminodesacetoxycephalosporanic Acid 22252-43-3 A604330 2-(2-Amino-6-(cyclopropylamino)-9H-purin-9-yl)-4-(hydroxymethyl)cyclopentanol A604530 4-[[(2-Amino-3,5-dibromophenyl)methylene]amino]cyclohexanol 1445719-53-8 A604603 trans-4-[[(2-Amino-3,5-dibromophenyl)methylene]amino]cyclohexanol 50910-53-7 A604605 (Ambroxol Impurity C) 2-Amino-3,5-dibromo-benzaldehyde 50910-55-9
Load more

Recommended publications
  • Individual Patient & Medication Factors That Invalidate Morphine
    Individual Patient & Medication Factors that Invalidate Morphine Milligram Equivalents Presented on June 7-8, 2021 at FDA Collaborative with various Federal Government Agency Stakeholders Jeffrey Fudin, PharmD, FCCP, FASHP, FFSMB Clinical Pharmacy Specialist & PGY2 Pain Residency Director Stratton VAMC, Albany NY Adjunct Associate Professor Albany College of Pharmacy & Health Sciences, Albany NY Western New England University College of Pharmacy, Springfield MA President, Remitigate Therapeutics, Delmar NY Disclosures Affiliation Role/Activities Abbott Laboratories Speaking, non-speakers bureau AcelRx Pharmaceuticals Acute perioperative pain (speakers bureau, consulting, advisory boards) BioDelivery Sciences International Collaborative publications, consulting, advisory boards Firstox Laboratories Micro serum testing for substances of abuse (consulting) GlaxoSmithKline (GSK) Collaborative non-paid poster presentations) Hisamitsu America Inc Advisory Board Hikma Pharmaceuticals Advisory Board Scilex Pharmaceuticals Collaborative non-paid publications Salix Pharmaceuticals Speakers bureau, consultant, advisory boards Torrent Pharmaceuticals Lecture, non-speakers bureau Learning Objectives At the completion of this activity, participants will be able to: 1. Explain opioid conversion and calculation strategies when developing a care plan for patients with chronic pain. 2. Assess patient-specific factors that warrant adjustment to an opioid regimen. 3. Identify important drug interactions that can affect opioid serum levels. 4. Describe how pharmacogenetic differences can affect opioid efficacy, toxicity, and tolerability. Not All Opioids are Created Equally Issues with MEDD & Opioid Conversion1-4 › Pharmacogenetic variability › Drug interactions › Lack of universal morphine equivalence › Specific opioids that should never have an MEDD – Methadone, Buprenorphine, Tapentadol, Tramadol 1. Fudin J, Marcoux MD, Fudin JA. Mathematical Model For Methadone Conversion Examined. Practical Pain Management. Sept. 2012. 46-51. 2. Donner B, et al.
    [Show full text]
  • Analysis of Oxycodone and Its Metabolites-Noroxycodone, Oxymorphone, and Noroxymorphone in Plasma by LC/MS with an Agilent ZORBAX Stablebond SB -C18 LC Column
    Analysis of Oxycodone and Its Metabolites-Noroxycodone, Oxymorphone, and Noroxymorphone in Plasma by LC/MS with an Agilent ZORBAX StableBond SB -C18 LC Column Application Note Pharmaceutical Authors Abstract Linda L. Risler Oxycodone and its oxidative metabolites (noroxycodone, oxymorphone, and Fred Hutchinson Cancer Research noroxymorphone) were analyzed by high performance liquid chromatography/mass Center, spectrometry (HPLC/MS), coupled with chromatographic separation by an Agilent Seattle, WA 98109 ZORBAX Rapid Resolution High Throughput (RRHT) StableBond SB-C18 column. The method used an ammonium acetate/acetonitrile gradient with detection by a mass Anne E. Mack spectrometer in electrospray mode with positive polarity. Spiked human plasma Agilent Technologies, Inc. samples underwent solid phase extraction (SPE) prior to LC/MS analysis. This method provided good linearity (R 2 > 0.9900) and reproducibility (< 10% difference between duplicates) for all compounds, while increasing productivity with a fast, efficient analysis and minimal solvent usage. Introduction Experimental Oxycodone was developed in 1916 as an opioid analgesic An Agilent 1100 Series LC/MS was used for this work: medication intended to replace the far too addictive analgesic at the time, heroin. Today, oxycodone is a Schedule II drug in • Agilent G1312A Binary Pump. Mobile phase A: 20 mM the US, which means, while it has proven medical uses, it is ammonium acetate, pH 4.0 and B: acetonitrile. Flow rate still considered highly addictive with the possibility of both was 0.300 mL/min. Hold 5% B for 2.33 minutes, then physical and psychological dependencies. Figure 1 shows increase B from 5% to 20% from 2.33 to 4.33 minutes, stop oxycodone and its metabolic scheme, yielding noroxycodone, time is 6 minutes, and post time is 4 minutes.
    [Show full text]
  • Revista Medica Hondurena
    Revista MEDICA HONDURENA (2* Época) ÓRGANO DEL COLEGIO MEDICO DE HONDURAS FUNDADA EN 1930 CONSEJO EDITORIAL RICARDO VILLELA VIDAL Director RIGOBERTO ARRIAGA CHINCHILLA Secretario Redactores: HENA CARDONA DE HERRERA ARMANDO PAVÓN AGUILERA CARLOS H. RIVERA MEDINA JORGE TULIO GALEAS A. Administración: "COLEGIO MEDICO DE HONDURAS" Oficina' "Colegio Médico de Honduras", Tegucigalpa, D. C. Tel. 22-5466 Apartado Postal N9 810 SE SOLICITA CANJE Imprenta LÓPEZ Y CÍA. EDITORIAL DR. RICARDO VILLELA-VIDAL Con la publicación de este número ha terminado la misión a nosotros enco- mendada, es decir, darle vida por un año al órgano oficial de publicidad del Colegio Médico de Honduras: La REVISTA MEDICA HONDURENA. Seguros de haber cumplido con nuestro deber, dejamos en manos de los nombrados para sucedemos nuestra querida Revista. Y decimos nuestra porque ya forman parte de nuestra existencia el trabajo, el recuerdo y nuestra voluntad convertida en páginas escritas que llegaron —seguramente— como mensajeras del pensamiento médico hondureño hasta nuestros colegas paisanos, y más allá de las fronteras hondureñas. Nuestro trabajo sólo fue posible siguiendo la ruta trazada por quienes, en años anteriores, dieron vida e importancia (con esfuerzo y sacrificio) a tas1 páginas de la REVISTA MEDICA HONDURENA. Es indudable que en cada año por venir, con mejor estilo, con más trabajo y mayor buena voluntad, la Revista Médica Hondureña irá adquiriendo belleza y más prestigio. Es que nuevos valores médicos llegan año con año para surtir sus páginas con el producto de sus estudios e investigaciones en el campo interminable de las ciencias médicas. Las páginas que llevan y traen los nuevos conocimientos médicos deben ser las primeras que se abran cada día ante los ojos de los médicos de aquí y de allá, porque no podemos avanzar sin estudiar lo nuevo, sin recordar lo histórico y sin esperar cada día la llegada de los adelantos científicos.
    [Show full text]
  • Presentation Slides (PDF)
    Urine toxicology testing to support pain management and treatment for substance use disorder Yifei Yang, PhD, DABCC Medical Director, Toxicology, ARUP Laboratories Assistant Professor, University of Utah Learning Objectives and Presentation Outline • Describe the general analytical workflow of urine drug testing • Understand the testing approaches for medication compliance in pain management and treatment for substance use disorder (SUD) settings • Recognize the utilities and limitations of qualitative and quantitative test results • Discuss case-based unexpected urine drug testing results and considerations for results interpretation Urine toxicology testing to support controlled substance prescription and monitoring • Pain management and SUD treatment • Long-term prescription of controlled substances • Various opiates: hydrocodone, oxycodone, etc. at various doses • Buprenorphine, with naloxone (Suboxone) • Co-medication with benzodiazepines, heroin, and other opiates can increase risk for over-dose • Urine toxicology testing is recommended: • Baseline testing prior to prescription • Annual monitoring (minimal), interval up to clinician discretion • Detect undisclosed medication use • Confirm expected medication use CDC Guideline for Prescribing Opioids for Chronic Pain. (2016) Centers for Disease Control and Prevention. Urine toxicology testing is used to confirm the presence of prescribed medications • Drug presence prevalence: • High positivity rate • Patients are mostly taking medications • Appropriate positive cutoffs are needed
    [Show full text]
  • Drug Plasma Half-Life and Urine Detection Window | January 2019
    500 Chipeta Way | Salt Lake City, UT 84108-1221 Phone: (800) 522-2787 | Fax: (801) 583-2712 www.aruplab.com | www.arupconsult.com DRUG PLASMA HALF-LIFE AND URINE DETECTION WINDOW | JANUARY 2019 URINE- PLASMA DRUG, DRUG METABOLITE(S)* COMMON TRADE AND STREET NAMES, NOTES DETECTION HALF-LIFEt WINDOWt STIMULANTS Benzedrine, dexedrine, Adderall, Vyvanse, speed; could be methamphetamine Amphetamine 7–34 hours 1–5 days metabolite; if so, typically < 30 percent of parent Cocaine Coke, crack; parent drug rarely observed due to short half-life 0.7–1.5 hours < 1 day Benzoylecgonine Cocaine metabolite 5.5–7.5 hours 1–2 days Desoxyn, methedrine, Vicks inhaler (D- and L-isomers not resolved; low concentrations Methamphetamine expected if the source is Vicks); selegeline (Atapryl, Carbex, Eldepryl, Zelapar) 6–17 hours 1–5 days metabolite Methylenedioxyamphetamine (MDA) MDA 11–17 hours 1–3 days Methylenedioxyethylamphetamine (MDEA) MDEA, MDE, Eve 6–11 hours 1–3 days Methylenedioxymethamphetamine (MDMA) MDMA, XTC, ecstasy, Molly 6–10 hours 1–3 days Methylphenidate Ritalin, Concerta, Focalin, Metadate, Methylin 1.4–4.2 hours < 1 day Ritalinic acid Methylphenidate metabolite 1.8–2.5 hours < 1 day Phentermine Adipex-P, Lomaira, Qsymia 19–24 hours 1–5 days OPIOIDS Buprenorphine Belbuca, Buprenex, Butrans, Suboxone, Subutex, Sublocade, Zubsolv 26–42 hours 1–7 days Norbuprenorphine, Glucuronides Buprenorphine metabolites 15–150 hours 1–14 days Included in many preparations; morphine metabolite; may be a contaminant if < 2 Codeine 1.9–3.9 hours 1–3 days percent of morphine Fentanyl Actiq, Duragesic, Fentora, Lazanda, Sublimaze, Subsys, Ionsys 3–12 hours 1–3 days Norfentanyl Fentanyl metabolite 9–10 hours 1–3 days Heroin Diacetylmorphine, dope, smack, dust; parent drug not detected.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Prediction of Drug Interactions with Methadone, Buprenorphine and Oxycodone from in Vitro Inhibition of Metabolism
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Prediction of Drug Interactions with Methadone, Buprenorphine and Oxycodone from In Vitro Inhibition of Metabolism Author(s): David E. Moody, Ph.D. Document No.: 250127 Date Received: July 2016 Award Number: 2011-DN-BX-K532 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this federally funded grant report available electronically. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. February 2016 Research and Development in Forensic Toxicology Prediction of drug interactions with methadone, buprenorphine and oxycodone from in vitro inhibition of metabolism Final Technical Report Submitted electronically to: U.S. Department of Justice Office of Justice Programs National Institute of Justice Prepared by: David E. Moody. Ph.D. Director of the Center for Human Toxicology, and Research Professor of Pharmacology and Toxicology [email protected] / 801-581-5117 NIJ Award Number: 2011-DN-BX-K532 Reporting Period: January 1, 2012 to December 31, 2015 Recipient Organization: University of Utah 75 South 2000 East, Room 222 Salt Lake City, UT 84112-8930 Organizational DUNS: 0090953650000 EIN: 876000525 This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S.
    [Show full text]
  • Clinical Pharmacokinetics 42: 223-282, No. 3, 2003
    Clin Pharmacokinet 2003; 42 (3): 223-282 DRUG INTERACTIONS 0312-5963/03/0003-0223/$30.00/0 © Adis International Limited. All rights reserved. Drug Interactions Between Antiretroviral Drugs and Comedicated Agents Monique M.R. de Maat,1 G. Corine Ekhart,1 Alwin D.R. Huitema,1 Cornelis H.W. Koks,1 Jan W. Mulder2 and Jos H. Beijnen1,3 1 Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands 2 Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands 3 Faculty of Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands Contents Abstract . 223 1. Methods . 224 2. Pharmacokinetics of Antiretroviral Drugs . 225 2.1 Nucleoside Reverse Transcriptase Inhibitors . 225 2.2 Non-Nucleoside Reverse Transcriptase Inhibitors . 225 2.3 Protease Inhibitors . 225 3. Mechanisms of Drug Interaction . 225 3.1 Pharmacokinetic Interactions . 227 3.1.1 Drug Absorption . 227 3.1.2 Metabolism and P-Glycoprotein . 227 3.1.3 Protein Binding . 273 3.1.4 Excretion . 274 3.2 Pharmacodynamic Interactions . 274 3.2.1 Efficacy . 274 3.2.2 Toxicity . 274 4. Practical Issues for Use of Interactions Table . 274 5. Conclusions . 275 Abstract HIV-infected individuals usually receive a wide variety of drugs in addition to their antiretroviral drug regimen. Since both non-nucleoside reverse trans- criptase inhibitors and protease inhibitors are extensively metabolised by the cytochrome P450 system, there is a considerable potential for pharmacokinetic drug interactions when they are administered concomitantly with other drugs metabolised via the same pathway. In addition, protease inhibitors are substrates as well as inhibitors of the drug transporter P-glycoprotein, which also can result in pharmacokinetic drug interactions.
    [Show full text]
  • Interpretation of Drug Testing Results in Medication Assisted Treatment
    Interpretation of Drug Testing Results in Medication Assisted Treatment By: Paul L. Cary Independent Forensic Toxicology Consultant What Does This Result Mean? Two-Step Testing Approach ■ screening test – designed to separate negative samples from samples that are “presumptively” positive ■ confirmation test – follow-up procedure designed to validate positive test results ■ why can’t you adjudicate based on the screening test results? ■ FALSE POSITIVES Drug tests & cross reactivity: ■ screening tests can and do react to “non-target” compounds ◆ amphetamines ◆ benzodiazepines ■ obtain list of interfering compounds from lab or on-site test vendor ■ study results have demonstrated accuracy rates for initial screening tests as low as 70% ■ confirm positive results Typical Cutoff Levels screening & confirmation ■ amphetamines * 500 ng/mL 250 ng/mL ■ benzodiazepines 300 ng/mL variable ■ cannabinoids * 20 & 50 ng/mL 15 ng/mL ■ cocaine (crack)* 150 ng/mL 100 ng/mL ■ opiates (heroin) * 300/2000 ng/mL variable ■ phencyclidine (PCP) * 25 ng/mL 25 ng/mL ■ alcohol 20 mg/dL 10 mg/dL ◆ * SAMHSA (formerly NIDA) drugs What is a “cutoff” level ? ■ cutoffs are not designed to frustrate CJ professionals ■ a drug concentration, administratively established for a drug test that allows the test to distinguish between negative and positive sample - “threshold” ■ cutoffs provide important safeguards: ◆ scientific purposes (detection accuracy) ◆ legal protections (evidentiary admissibility) ■ measured in ng/mL = ppb Cutoffs and False Positives as you lower you
    [Show full text]
  • Review Memorandum
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE A. 510(k) Number: K130082 B. Purpose for Submission: New Device C. Measurand: Amphetamine, Barbiturates, Cocaine, Marijuana, Methadone, Methamphetamine, Morphine, Oxycodone, Phencyclidine D. Type of Test: Qualitative immunochromatographic tests for drugs of abuse in urine E. Applicant: GenPrime Inc. F. Proprietary and Established Names: The GenPrime Drugs of Abuse (DOA) Reader System G. Regulatory Information: 1. Regulation section: 21 CFR §862.3100, Amphetamine Test System 21 CFR §862.3150, Barbiturate Test System 21 CFR §862.3250, Cocaine and cocaine metabolite Test System 21 CFR §862.3870, Cannabinoid Test System 21 CFR §862.3620, Methadone Test System 21 CFR §862.3610, Methamphetamine Test System 21 CFR §862.3640, Morphine test system 21 CFR §862.3650, Opiate Test System Phencyclidine, Unclassified 21 CFR §862.2400, Densitometer/Scanner (integrating, reflectance, TLC, or radiochromatogram) for clinical use 2. Classification: Class II – for all except Phencyclidine and the Densitometer/Scanner Phencyclidine – Unclassified Densitometer/Scanner – Class I 3. Product code: DKZ, DIS, DIO, LDJ, DJR, DJC, DJG, LCM, DNK, JQT 4. Panel: Clinical Toxicology (91) and Clinical Chemistry (75) H. Intended Use: 1. Intended use(s): See Indications for Use below. 2. Indication(s) for use: The GenPrime Drugs of Abuse (DOA) Reader System consists of the GenPrime DOA Reader, GenPrime DOA Windows®-compatible Software and compatible qualitative immunochromatographic, OS Cup and Split Key Cup (SK Cup) test devices. The GenPrime DOA Reader System is for in vitro diagnostic use and is intended for prescription use in laboratories, point-of-care, and workplaces by trained users.
    [Show full text]
  • Number: K040257 B. Analyte: THC An
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE ONLY TEMPLATE A. 510(k) Number: k040257 B. Analyte: THC and carboxy-THC C. Type of Test: Qualitative screening test: immunoassay Quantitative confirmatory test: GC-MS-MS D. Applicant: Quest Diagnostics, Inc. E. Proprietary and Established Names: Quest Diagnostics Haircheck-DT (THC) F. Regulatory Information: 1. Regulation section: 21 CFR § 862.3870 2. Classification: II 3. Product Code: LDJ 4. Panel: Toxicology (91) G. Intended Use: 1. Intended use(s): Refer to Indications for use. 2. Indication(s) for use: The Quest Diagnostics HairCheck-DT (THC-COOH) is a bipartite device employing enzyme-linked immunosorbent assay (ELISA) for qualitative screening at 1.0 pg/mg hair of THC-COOH and Gas Chromatography – Mass Spectroscopy – Mass Spectroscopy (GC-MS-MS) for confirmation and the final quantitative reporting of THC-COOH in human hair samples for the purpose of identifying chronic marijuana use. This process has not been evaluated with hair specimens other than head. This process is intended exclusively for in-house professional use only. The process is not intended for sale to anyone. Clinical consideration and professional judgement should be applied to any drug of abuse test result. Page 2 of 16 The device is for in vitro diagnostic use. The device is for prescription use only. 3. Special condition for use statement(s): The Quest Diagnostics HairCheck-DT (THC-COOH) combines a screening method (immunoassay) with a confirmation method (GC-MS-MS) in one test system. A negative screening result is reported as negative. A presumptive positive screening result is not reported until it has been confirmed by GC- MS-MS.
    [Show full text]
  • Federal Register/Vol. 85, No. 230/Monday, November 30, 2020
    76604 Federal Register / Vol. 85, No. 230 / Monday, November 30, 2020 / Notices notifications disclosing all changes in Act on September 18, 2020 (85 FR DEPARTMENT OF JUSTICE membership. 58390). Drug Enforcement Administration On September 10, 2018, CONFERS Suzanne Morris, [Docket No. DEA–688E] filed its original notification pursuant to Chief, Premerger and Division Statistics, Section 6(a) of the Act. The Department Antitrust Division. Established Aggregate Production of Justice published a notice in the [FR Doc. 2020–26362 Filed 11–27–20; 8:45 am] Federal Register pursuant to Section Quotas for Schedule I and II Controlled BILLING CODE P Substances and Assessment of 6(b) of the Act on October 19, 2018 (83 Annual Needs for the List I Chemicals FR 53106). Ephedrine, Pseudoephedrine, and The last notification was filed with DEPARTMENT OF JUSTICE Phenylpropanolamine for 2021 the Department on May 1, 2020. A notice was published in the Federal Antitrust Division AGENCY: Drug Enforcement Register pursuant to Section 6(b) of the Administration, Department of Justice. Act on May 28, 2020 (85 FR 32049). Notice Pursuant to the National ACTION: Final order. Cooperative Research and Production Suzanne Morris, Act of 1993—Cooperative Research SUMMARY: This final order establishes Chief, Premerger and Division Statistics, Group on AC2AT–II the initial 2021 aggregate production Antitrust Division. quotas for controlled substances in [FR Doc. 2020–26358 Filed 11–27–20; 8:45 am] Notice is hereby given that, on schedules I and II of the Controlled Substances Act and the assessment of BILLING CODE 4410–11–P November 19, 2020, pursuant to Section 6(a) of the National Cooperative annual needs for the list I chemicals Research and Production Act of 1993, ephedrine, pseudoephedrine, and DEPARTMENT OF JUSTICE 15 U.S.C.
    [Show full text]